Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer

• Main Authors: Meiyu Wu (Author), Shuxia Qin (Author), Liting Wang (Author), Chongqing Tan (Author), Ye Peng (Author), Xiaohui Zeng (Author), Xia Luo (Author), Lidan Yi (Author), Xiaomin Wan (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the healthcare system...